This phase 3b clinical trial focused on safety and efficacy of the anti-IL-23 inhibitor in scalp psoriasis. Patients taking tildrakizumab had scalp improvement by 16 weeks, which continued through ...

The last patient in the ongoing Whistler Phase 3b clinical trial investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in IOP lowering is now expected to ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

Discover a study where patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.

ATLANTA, March 7, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating ...

Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development UpdateMore patients on NCX 470 achieve an ...